# Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).

> **NCT00501202** · PHASE2 · COMPLETED · sponsor: **SK Life Science, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Diabetic Neuropathy, Painful
- Diabetic Neuralgia
- Diabetic Polyneuropathy
- Diabetic Mononeuropathy

## Interventions

- **DRUG:** placebo
- **DRUG:** RWJ-333369 (carisbamate)

## Key facts

- **NCT ID:** NCT00501202
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2018-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501202, "Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00501202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*